Keeping you updated about the latest first patient implants, we bring to your attention a device we have been following since February of last year. VentrAssist, a third generation cardiac assist system that weighs just 298 grams (10oz) and measures 60mm (2.5 inches) in diameter, is now in vivo:
Ventracor Limited announced the first patient has been implanted with the VentrAssist in a new study designed to build on clinical momentum from the CE Mark Trial and prepare for European market launch.
The BRACE study (Baseline Results And Cost Effectiveness) will add to the body of evidence for the performance of the VentrAssist left ventricular assist device (LVAD) in up to 10 new centres in Europe. The new centres are in addition to the current Australian, NZ and European sites.
The BRACE study is a key component of Ventracor’s commercialisation strategy to rapidly grow revenues after the anticipated CE Mark approval in early 2007…